BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control OngoingThis study is testing a four-drug combination given before surgery for pancreatic cancer that can be removed. The treatment includes two chemotherapy drugs and two immunotherapy drugs designed to help the immune system attack the cancer. The main goals are to see if this approach…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New hope in fight against pancreatic cancer: trial tests Cutting-Edge drug combos
Disease control OngoingThis study is testing new drug combinations for people with pancreatic cancer that has not spread widely. It compares these experimental treatments to standard chemotherapy. The goal is to see if the new approaches can better shrink tumors before surgery or control the disease fo…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
Nanoparticle 'Booster' tested to make radiation more powerful against tough pancreatic tumors
Disease control TerminatedThis early-stage study is testing a new experimental treatment called NBTXR3 for people with locally advanced pancreatic cancer that is difficult to remove with surgery. The treatment involves injecting tiny nanoparticles directly into the tumor, which are then activated by a sta…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC